AEWS1221: Randomized Phase III Trial Evaluating the Addition of the IGF-IR Monoclonal Antibody Gantitumab (AMG 479, NSC# 75008, IND# 120449) to Multiagent Chemotheraapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma.

Protocol: 
AAAO8855
Phase: 
III

AEWS1221: Randomized Phase III Trial Evaluating the Addition of the IGF-IR Monoclonal Antibody Gantitumab (AMG 479, NSC# 75008, IND# 120449) to Multiagent Chemotheraapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma.

This randomized phase III trial studies how well combination chemotherapy with
or without ganitumab works in treating patients with newly diagnosed Ewing
sarcoma that has spread to other parts of the body. Monoclonal antibodies, such
as ganitumab, may block tumor growth in different ways than chemotherapy by
targeting certain cells. Chemotherapy drugs work to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. It is not yet known whether combination
chemotherapy is more effective with or without ganitumab in treating patients
with newly diagnosed Ewing sarcoma.

Are you Eligible? (Inclusion Criteria)

-Subjects up to 50 years of age are eligible for this study.
-Patients with newly diagnosed Ewing sarcoma or peripheral primitive
neuroectodermal tumor (PNET) arising from bone or soft tissue and with
metastatic disease involving lung, bone, bone marrow, or other metastatic site.
-Patients must also meet all eligibility criteria as outlined in the study
protocol.

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States